SWOG clinical trial number
S0437
Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed with Prostate Cancer
Closed
Phase
Accrual
53%
Abbreviated Title
PCPT Long Term Follow Up
Activated
09/01/2005
Closed
03/01/2009
Participants
PCPT Institutions with Participants who were Diagnosed with Prostate Cancer on or Before 12/31/03
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Participants randomized in the Prostate Cancer Prevention Trial (PCPT, SWOG-9217) who were diagnosed with prostate cancer on or before December 31, 2003
Other Clinical Trials
SWOG Clinical Trial Number
S2419
Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase